SLC26A4 correlates with homologous recombination deficiency and patient prognosis in prostate cancer.

Cong LuoZhi LiuYu GanXiaomei GaoXiongbing ZuYe ZhangWenrui YeYi Cai

Published in: Journal of translational medicine (2022)

This study introduces HRDscore to quantify the HRD pattern of individual PCa patients. Meanwhile, SLC26A4 is a novel biomarker and can reasonably predict the prognosis and HRD in PCa.

Keyphrases

prostate cancer
end stage renal disease
dna damage
dna repair
ejection fraction
newly diagnosed
chronic kidney disease
radical prostatectomy
prognostic factors
case report
oxidative stress
replacement therapy
smoking cessation